Fresh from announcing a deal to acquire the USA's Rebiotix Inc. and moving into the microbiome drug development space, Ferring Pharmaceuticals AS is also targeting the hot area of gene therapy with a late-stage licensing deal for a novel bladder cancer treatment from Finland's FKD Therapies OY.
The Swiss firm has taken the option, dependent on US approval, to secure global commercialization rights to rAd-IFN/Syn3 (nadofaragene firadenovec/Syn3),...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

